Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.Blue DNA illustrationPhoto of a series of test tubes.Scientific microscope with visual representation of DNA helix

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis

November 12, 2021

Trethera announced that the FDA has granted Orphan Drug Designation to TRE‑515 for optic neuritis, a rare autoimmune disease causing vision loss. The designation complements existing ADEM orphan status and offers clinical trial and regulatory advantages.

Read More

Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515

October 15, 2021

Trethera has dosed the first patient in a landmark Phase 1 solid tumor study with TRE‑515, the first-in-class dCK inhibitor. This multi-site trial will evaluate safety, tolerability, and biomarker engagement in up to 36 patients with diverse solid tumors.

Read More

Globally Recognized Multiple Sclerosis Expert, Dr. Lawrence “Larry” Steinman, Joins Trethera Scientific Advisory Board

May 25, 2021

Trethera welcomed Dr. Lawrence “Larry” Steinman, a world-renowned MS researcher and Stanford professor, to its Scientific Advisory Board. He’ll advise on TRE‑515’s development in MS and autoimmune neurologic diseases based on his decades of translational research leadership.

Read More

Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy

April 19, 2021

Trethera received FDA approval to initiate a Phase 1, first-in-human monotherapy trial of its oral dCK inhibitor TRE‑515 in solid tumors. The open-label dose escalation study, led by UCLA, will evaluate safety, pharmacokinetics, and biomarker engagement.

Read More

Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor

March 16, 2021

Trethera announced the appointment of Frank Baxter, Jefferies Chairman Emeritus and former U.S. Ambassador to Uruguay, as special advisor. He will counsel the board on financing strategies including private equity, public markets, and debt options.

Read More